High expression of GUSBP11 in renal cancer is associated with a smaller tumor size and absence of metastasis (Jia et al., 2022), and SLC2A1-AS1 inhibits hepatocellular carcinoma progression and glycolysis through the STAT3/FOXM1/GLUT1 axis (Shang et al., 2020). Here, GUSBP11 is linked to neoplasm.